Corlanor Solution
Product Images NDC 55513-813

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Corlanor (NDC 55513-813). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Chemical Structure Of Ivabradine (Corlanor 01)

Chemical structure diagram of ivabradine, the active ingredient in Corlanor. The structure shows the molecular arrangement including methoxy groups and ring systems, annotated with HCl.*

FDA Label Image

Figure 2. Impact Of Coadministered Drugs On The Pharmacokinetics Of Corlanor (Corlanor 02)

A forest plot chart showing pharmacokinetic (PK) changes in ivabradine exposure with co-administration of various drugs, measured by Cmax and AUC. It displays fold changes and 90% confidence intervals relative to ivabradine alone. The chart categorizes drug interactions by strong, moderate, and CYP3A4 inducers, with recommendations ranging from contraindicated to no dose adjustment needed.*

FDA Label Image

Figure 3. Shift: Time To First Event Of Primary Composite Endpoint (Corlanor 03)

A line graph showing the proportion of subjects with heart failure hospitalization or cardiovascular death over 36 months from randomization. The graph compares two groups: Corlanor and placebo, with Corlanor showing a consistently lower proportion. Numbers of subjects at risk are listed below the x-axis for both groups at various time points.*

FDA Label Image

Figure 4. Effect Of Treatment On Primary Composite Endpoint In Subgroups (Corlanor 04)

A forest plot comparing Corlanor versus placebo across various patient subgroups including age, sex, race, cause of heart failure, weight, baseline heart rate, NYHA class, baseline LVEF, beta blocker use, aldosterone antagonist use, diabetes, and hypertension status. The plot presents hazard ratios with 95% confidence intervals for each subgroup, indicating the relative effect of Corlanor compared to placebo.*

FDA Label Image

Ndc 55513-800-80amgen®corlanor ®(ivabradine) Tablets5 mgeach Tablet Contains 5 mg Ivabradine Equivalent To 5.39 mg Ivabradine As Hydrochloride.oral Use.store At 25°c, Excursions Permitted To 15°c (30°C.Keep out of the sight and reach of children.Rx Only180 Film-coated tabletsManufactured for Amgen Inc.One Amgen Center DriveThousand Oaks, CA 91320-1799Made in France)

Illustration of a transparent medicine cup with measurement markings, commonly used for oral liquid medications.*

FDA Label Image

Ndc 55513-810-80amgen®corlanor ®(ivabradine) Tablets7.5 mgeach Tablet Contains 7.5 mg Ivabradine Equivalent To 8.085 mg Ivabradine As Hydrochloride.oral Use.store At 25°c, Excursions Permitted To 15°c (30°C.Keep out of the sight and reach of children.Rx Only180 Film-coated tabletsManufactured for Amgen Inc.One Amgen Center DriveThousand Oaks, CA 91320-1799Made in France)

An illustration diagram of a syringe showing labeled components: syringe markings, plunger stopper, and plunger, indicating parts of the device used for measuring and administering liquid medication.*

FDA Label Image

Corlanor 07

Packaging label for Corlanor tablets, film coated, containing 7.5 mg of ivabradine. The box shows the brand name Corlanor and includes an expiration date on the side panel. The labeler is Amgen Inc. The box design features a white background with yellow accents and black text.*

FDA Label Image

Corlanor 08

Corlanor ivabradine oral solution 5 mg/5 mL unit dose pouch label by Amgen Inc. The label includes dosage form (oral solution) and highlights that it is for oral administration only, with storage and disposal instructions noted. The package appears to be a foil pouch containing a 5 mL ampule.*

FDA Label Image

Corlanor 09

Corlanor (ivabradine) oral solution label presenting a 5 mg/5 mL strength. The label indicates the product is for oral administration only and highlights the 5 mL ampule volume. The labeler is Amgen Inc. The packaging includes barcodes and storage instructions.*

FDA Label Image

Corlanor 0a

An illustration showing three items commonly used for oral liquid medication administration: a foil pouch labeled with product information, a clear dosing cup, and a syringe without a needle. The pouch indicates the drug Corlanor with suggestions for measurement, the cup provides dosing volume markings, and the syringe is marked for accurate liquid measurement.*

FDA Label Image

Corlanor 0b

An instructional illustration showing a hand removing a single-dose vial from a foil pouch labeled with Corlanor 5 mg. A pair of scissors is depicted cutting open the pouch. The vial is intended for oral use of ivabradine tablets as film-coated tablets in liquid form, labeled by Amgen Inc.*

FDA Label Image

Corlanor 0c

Illustration showing a pair of hands demonstrating how to open a small, sealed vial by twisting off the top cap. The vial is partially filled with liquid. This instructional image likely depicts the proper method to open a single-dose vial or ampule.*

FDA Label Image

Corlanor 0d

An instructional illustration showing a hand dispensing a liquid dose from a bottle into a small cup. The image demonstrates pressing the bottle to release the medication, with arrows indicating the action and flow of the liquid.*

FDA Label Image

Corlanor 0e

An instructional diagram of a syringe showing labeled parts including syringe markings, plunger stopper, and plunger, illustrating the components used for measuring and administering medication.*

FDA Label Image

Corlanor 0f

An illustration showing hands using a syringe to measure liquid from a cup, with an arrow pointing upward indicating the syringe plunger is being pulled up. This likely depicts the process of drawing liquid from the cup into the syringe.*

FDA Label Image

Corlanor 10

An instructional illustration showing how to measure and administer a 3 mL dose of Corlanor oral solution using an oral syringe. The image depicts hands holding the syringe with a plunger stopper, alongside a clear measurement scale on the syringe barrel and a cup below.*

FDA Label Image

Corlanor 11

An instructional illustration showing a child receiving an oral liquid medication via an oral syringe. The syringe is inserted gently into the child's mouth, positioned for medication administration by a caregiver.*

FDA Label Image

Corlanor 12

An instructional illustration showing how to properly remove and reinsert the plunger in a syringe. The top image depicts pushing the plunger out, while the bottom image shows pulling the plunger back in, indicated by arrows.*

FDA Label Image

Corlanor 13

Corlanor (ivabradine) 5 mg film-coated tablets packaging label by Amgen Inc. The label includes the dosage strength of 5 mg, a count of 60 tablets, and storage instructions. It shows the NDC number 55513-800-60 and states that the product is made in Italy. The label also features the Amgen logo and barcode, along with usage and safety instructions to keep out of reach of children.*

FDA Label Image

Corlanor 14

Label for Corlanor 7.5 mg film-coated tablets (ivabradine), an oral prescription drug by Amgen Inc. The label states each tablet contains 7.5 mg ivabradine equivalent to 8.085 mg ivabradine as hydrochloride. The package contains 60 tablets. Storage instructions and prescription-only status are also noted.*

FDA Label Image

Corlanor 15

Corlanor (ivabradine) oral solution 5 mg/5 mL in sterile ampules. The label indicates storage instructions, a caution for pharmacists to dispense with both a medicine cup and oral syringe, and states the package contains 28 ampules. The product is labeled for prescription use by Amgen Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.